Schreiber 2018.

Methods	Parallel multi‐centre randomised controlled trial
Participants	Women with an anembryonic pregnancy, embryonic or fetal death with a gestational age between five and 12 weeks
Interventions	200 mg of mifepristone, administered orally, followed by 800 mcg of misoprostol, administered vaginally (mifepristone‐pretreatment group) or 800 mcg of misoprostol alone, administered vaginally (misoprostol‐alone group)
Outcomes	Treatment success (defined as complete expulsion without the need of additional vacuum aspiration within 30 days after treatment) Secondary outcomes reported were rate of vacuum aspiration, blood transfusion, pelvic infection, side effects of medication such as nausea, diarrhoea, headache and fever.
Funding	Supported by the National Institute of Child Health and Human Development of the National Institutes of Health (Eunice Kennedy Shriver award number R01‐HD0719‐20 [to Dr. Schreiber] and Women’s Reproductive Health Research award number K12‐HD001265‐18 [to Dr. Sonalkar]).
Declarations of interest	Dr. Creinin reports receiving consulting fees from Danco Laboratories. No other potential conflict of interest relevant to this article was reported.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Participants were randomly assigned in permuted blocks of two to eight, stratified according to trial site, with the use of Research Electronic Data Capture software".
Allocation concealment (selection bias)	Low risk	Quote: "Participants were randomly assigned in permuted blocks of two to eight, stratified according to trial site, with the use of Research Electronic Data Capture software."
Incomplete outcome data (attrition bias) All outcomes	Low risk	Comment: 2 women lost to follow‐up in intervention arm, 1 in the control arm. For 2 women, reasons for lost to follow‐up were not mentioned. In 1 women there was a suspicion of caesarean section scar pregnancy
Selective reporting (reporting bias)	High risk	Quote: "assessments of quality of life, costs, and biomarkers that predict complete gestational sac expulsion were performed, but the data are not presented here". It is not mentioned if these outcomes are or will be presented elsewhere.
Other bias	Low risk	No other bias could be detected
Blinding of participants and personnel (performance bias) All outcomes	High risk	Comment: no placebo was used, therefore blinding was not possible for both personnel and participants.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	At the initial follow‐up visit, an investigator who was unaware of the treatment‐group assignments assessed the outcome by means of endovaginal ultrasonography.